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Malassezia pachydermatis is a commonly isolated yeast in veterinary der-
matology that can produce biofilms in vitro and in vivo, lowering its susceptibility 
to antimicrobial drugs. The aim of this study was to determine and compare the in 
vitro susceptibility of planktonic cells and biofilms of M. pachydermatis isolates to 
ketoconazole and itraconazole. The presence of biofilm formation was confirmed 
by crystal violet staining and absorbance measurement at 595 nm wavelength, and 
by a scanning electron microscopy method. Cell viability was determined by the 
Celltiter 96 Aqueous One solution assay containing a water-soluble tetrazolium 
compound (MTS) with absorbance measurement at 490 nm. Planktonic cell 
minimum inhibitory concentrations (MICs) and minimum fungicidal concentra-
tions (MFCs) of ketoconazole and itraconazole were very low: MIC90 and MFC90 
were 0.032 and 0.125 µg/ml for ketoconazole, while 0.063 and 0.25 µg/ml for 
itraconazole, respectively. Also, the half maximal effective concentrations (EC50) 
of itraconazole were higher for planktonic cells and biofilms compared to keto-
conazole. The EC50 values of ketoconazole were 18–169 times higher and those of 
itraconazole 13–124 times higher for biofilms than for planktonic cells. Biofilm 
EC50 levels exceeded MICs 103–2060 times for ketoconazole and 84–1400 times 
for itraconazole. No significant difference was found between these values of the 
two substances. In conclusion, biofilms of all examined M. pachydermatis strains 
were much less susceptible to ketoconazole and itraconazole than their planktonic 
forms. 
Key words: Biofilm, itraconazole, ketoconazole, Malassezia pachyderma-
tis, planktonic  
Malassezia pachydermatis is a frequently isolated commensalistic yeast in 
veterinary dermatology (Bond, 2010; Outerbridge, 2006). It is a member of the 
normal skin flora, but can cause secondary dermatitis or external otitis in dogs and 
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cats with atopic dermatitis, cutaneous food adverse reactions, ectoparasite infes-
tations, immunosuppression, primary keratinisation defects or endocrinopathies 
(Bond, 2010; Outerbridge, 2006). Common treatments for Malassezia dermatitis 
and otitis include antifungal agents like polyenes, azoles, allylamines or chlor-
hexidine. Antifungals belonging to the azole group are one of the most effective 
and the most frequently used drugs in the management of the infection, keto-
conazole and itraconazole being the most active against this microorganism with 
very low MICs (Brito et al., 2007; Bond, 2010; Jesus et al., 2011; Jerzsele et al., 
2013). However, yeasts including malasseziae can produce biofilms in vitro 
(Cannizzo et al., 2007; Figueredo et al., 2012), decreasing susceptibility to the 
antimicrobial drugs used. It was reported that Candida albicans, Cryptococcus 
neoformans, Aspergillus fumigatus, Pneumocystis spp. and Coccidioides immitis 
might also be able to produce fungal biofilms in humans (Cannizzo et al., 2007; 
Martinez and Fries, 2010). Biofilms are extracellular matrices produced by micro-
organisms (primarily bacteria and fungi) which help the pathogens attach to vi-
able and non-viable surfaces (Van Minnebruggen et al., 2010). Biofilm formation 
in Candida albicans resulted in a 30- to 2000-fold decrease in sensitivity to cer-
tain antifungals including ketoconazole (Martinez and Fries, 2010; Vandeputte et 
al., 2012). Figueredo et al. (2013) reported that M. pachydermatis biofilms ex-
hibited high-level resistance to several antifungals including azoles, at least 3 di-
lutions higher as compared to planktonic cells.  
The aim of this study was to determine and compare the in vitro suscepti-
bility of planktonic cells and biofilms of M. pachydermatis strains of canine ori-
gin to ketoconazole and itraconazole. 
 
 
Materials and methods 
Malassezia pachydermatis isolates 
Sixteen strains of M. pachydermatis were examined. All of the strains 
were isolated between 2009 and 2011 in Hungary from dogs suffering from 
clinical signs of external otitis or superficial dermatitis. Clinical specimens were 
obtained using a sterile dry cotton swab. Malasseziae were identified on the basis 
of colony morphology on Sabouraud agar, microscopic identification and growth 
on agar without lipid supplementation (Guillot et al., 1996). The strains were 
stored at –80 °C in Sabouraud dextrose broth (Biolab Co. Ltd., Budapest, Hun-
gary) and 20% glycerol. 
Biofilm production and planktonic cells of M. pachydermatis 
Strains grown in Sabouraud dextrose liquid broth at 32 °C for 72 h were 
centrifuged at 3000 g for 10 min and resuspended in physiological saline. The 
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optical density of the suspension at 600 nm was set to 0.1 resulting in an approx. 
106 colony forming units (CFU)/ml viable cell count confirmed by agar plate 
counting. 
Biofilm production and subsequent evaluation was carried out according to 
the method of Hawser and Douglas (1994), with some modifications as recom-
mended by Nett et al. (2011). Briefly, a sterile, disposable silicone elastomer Foley 
catheter was cut into standardised segments of 10 mm. The surface of these 
catheters was scraped with sterile, gamma-sterilised scalpel blades to enhance the 
attachment of yeast cells. Twenty-five μl of the yeast suspension (106 CFU/ml) 
was pipetted on catheter segment surfaces, put in a thermostat and incubated at 
32 °C for 1 h (attachment phase) to facilitate adherence of the yeast cells. The 
segments were submerged in 1 ml of Sabouraud broth in a 24-well microplate 
(Corning, California, USA) and incubated at 32 °C for 8 h. After 8 h the medium 
was replaced by Sabouraud broth containing different concentrations of keto-
conazole (Sigma, St. Louis, USA) or itraconazole (Sigma, St. Louis, USA). Stock 
solutions of the azoles were prepared in dimethyl sulphoxide (DMSO) and the 
final concentrations in the microplates were set in the range of 0.004 to 32 µg/ml 
for both drugs. Fungal suspensions containing the antifungals were placed in 
triplicates in a thermostat and incubated at 32 °C for 72 h. By omitting the 
placement of cells on catheter segments and the attachment phase, they grew in 
the planktonic form. 
The presence of biofilm formation was confirmed by crystal violet stain-
ing and absorbance measurement at 595 nm wavelength (Jin et al., 2003) and a 
scanning electron microscopy (SEM) method described by Figueredo et al. (2012) 
utilising a ZEISS EVO MA10 scanning electron microscope. The samples were 
dehydrated with increasing concentrations of ethanol (20%, 40%, 50%, 70% and 
90%), then coated with gold with a high-vacuum evaporator. 
Determination of half maximal effective concentrations (EC50)  
and MFC values of ketoconazole and itraconazole 
Cell viability was determined by the Celltiter 96 Aqueous One solution as-
say (Promega, Madison, USA), containing a water-soluble tetrazolium com-
pound (MTS). Formazan produced by viable yeasts was measured by absorbance 
at 490 nm and was directly proportional to the number of living cells. Dose-
response curves were used to determine EC50 values (effective concentration 
50%) of ketoconazole and itraconazole (Hawser and Douglas, 1994; Nett et al., 
2011). All assays were performed in triplicates. For planktonic cells, also the 
minimum inhibitory concentration (MIC) and the minimum fungicidal concen-
tration (MFC) of the drugs were determined. The threshold of resistance was 
≤ 0.125 µg/ml in the case of both drugs according to the CLSI (Clinical Labora-
tory Standards Institute) guidelines. MFC was determined by agar plate CFU 
counting and defined as the concentration of the drug that decreased viable cell 
476 JERZSELE et al. 
Acta Veterinaria Hungarica 62, 2014 
number by 99.9%. MIC90 and MFC90 were calculated as the concentrations of 
drugs that inhibit/kill 99.9% of fungi in 90% of the strains investigated. 
Statistical analysis 
The paired Student’s t-test was used to evaluate the differences between 
MIC, MFC and EC50 mean values of the two antifungal agents. A value of P < 
0.05 was considered to be statistically significant. 
 
 
Results 
All of the tested 16 M. pachydermatis isolates were able to produce biofilms 
on the catheter surface, as confirmed by crystal violet staining and SEM. A SEM 
picture of an 8 hours old M. pachydermatis biofilm is shown in Fig. 1. 
 
Fig. 1. Scanning electron micrograph of an 8 hours old Malassezia pachydermatis biofilm  
(Zeiss Evo MA10; magnification: × 2500) 
 
Planktonic cells were much more sensitive than biofilms to both of the 
drugs tested. The susceptibility of the investigated M. pachydermatis strains to 
ketoconazole and itraconazole in biofilms and free-floating planktonic cells is 
shown in Table 1. MFC/MIC ratios were between 2 and 4, indicating excellent in 
vitro fungicidal effect of the azoles against M. pachydermatis. MIC90 and MFC90 
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Table 1 
Minimum inhibitory concentration (MIC), minimum fungicidal concentration (MFC) and EC50 (concentration able to reduce formazan formation 
by 50%) values of ketoconazole and itraconazole in planktonic cells and biofilms of Malassezia pachydermatis isolated from dogs 
Ketoconazole Itraconazole 
Planktonic cells Biofilm Planktonic cells Biofilm Strain No. 
EC50 MIC MFC EC50 
Biofilm EC50/
Planktonic 
EC50 EC50 MIC MFC EC50 
Biofilm EC50/
Planktonic 
EC50 
 1 0.09 0.016 0.063 2.06 23 0.09 0.032 0.125 2.7 30 
 2 0.06 0.008 0.032 2.68 41 0.11 0.016 0.063 2.64 24 
 3 0.11 0.016 0.063 1.85 18 0.17 0.016 0.063 2.23 13 
 4 0.05 0.004 0.016 2.47 51 0.20 0.032 0.125 3.1 16 
 5 0.19 0.008 0.032 14.42 74 0.23 0.016 0.063 9.8 43 
 6 0.26 0.032 0.125 13.39 52 0.40 0.032 0.125 17.9 45 
 7 0.07 0.008 0.032 3.19 44 0.09 0.008 0.032 4.8 53 
 8 0.10 0.008 0.032 16.48 169 0.09 0.008 0.032 11.2 124 
 9 0.21 0.032 0.125 12.36 59 0.17 0.016 0.063 9.95 59 
 10 0.11 0.016 0.063 4.64 41 0.18 0.032 0.125 11.3 63 
11 0.34 0.032 0.125 8.76 26 0.39 0.032 0.125 9.67 25 
12 0.26 0.063 0.25 6.49 25 0.33 0.063 0.25 8.9 27 
13 0.07 0.016 0.063 2.78 38 0.10 0.016 0.063 4.72 47 
14 0.09 0.008 0.032 4.02 45 0.15 0.032 0.063 6.87 46 
15 0.25 0.032 0.125 10.82 43 0.35 0.063 0.25 14.3 41 
16 0.22 0.016 0.063 9.99 46 0.47 0.125 0.25 13.76 29 
Mean ± SD 0.16 ± 0.09   7.27 ± 5.01 49.5 ± 34.9 0.22 ± 0.13   8.37 ± 4.74 42.7 ± 26.3
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for ketoconazole were 0.032 and 0.125 µg/ml, while for itraconazole 0.063 and 
0.25 µg/ml, respectively. Although these values proved to be higher in the case 
of ketoconazole, differences in individual sensitivity were without statistical sig-
nificance (P > 0.05). Also, the mean EC50 values for itraconazole were higher for 
planktonic cells and biofilms compared to ketoconazole but without significant 
differences (P > 0.05). EC50 values of ketoconazole were 18–169 times higher, while 
those of itraconazole 13–124 times higher for biofilms than for planktonic cells. 
Biofilm EC50 levels exceeded the MICs 103–060 times for ketoconazole and 84–
1400 times for itraconazole. No significant difference was found between these 
values for the two substances.  
 
Discussion 
The MICs and MFCs of ketoconazole and itraconazole were very low as 
expected from previous studies (Jesus et al., 2011; Cafarchia et al., 2012), and no 
resistant strain was found to either of the azoles according to the CLSI break-
points, similarly as reported in earlier studies (Brito et al., 2007). Figueredo et al. 
(2013) reported low MICs for ketoconazole and itraconazole, with higher MICs 
for ketoconazole. In our study, ketoconazole was more effective against both 
planktonic cells or biofilms. In our study, biofilm EC50 levels exceeded the MICs 
103–2060 times for ketoconazole and 84–1400 times for itraconazole. In the 
study of Figueredo et al. (2013), although using a different methodology, M. 
pachydermatis biofilm MICs were approx. 8 times higher than those of plank-
tonic cells. In our study, however, the EC50 values of ketoconazole and itracona-
zole were 18–169 and 13–124 times higher, respectively. These results show 
trends similar to those observed in earlier studies performed on Candida albicans 
strains in human medicine, where a 30- to 2000-fold higher EC50 was found as 
compared to the relevant MICs (Hawser and Douglas, 1995). The M. pachyder-
matis isolates examined in our study were more susceptible to ketoconazole and 
itraconazole than Candida yeasts with lower MICs and EC50s, as has also been 
demonstrated by Brito et al. (2007). 
The primary clinical significance of biofilm formation of yeasts in human 
medicine is their ability to colonise intravenous catheters and cause bloodstream 
infections (Leonidou and Gogos, 2010). The fungal species most commonly as-
sociated with these infections belong to the Candida genus, although Malassezia 
spp. are frequently isolated in neonatal intensive care units (Van Belkum et al., 
1994). There are no reports on M. pachydermatis causing septicaemia in veteri-
nary medicine. However, its occurrence in veterinary dermatology is common 
(Outerbridge, 2006). According to Cafarchia et al. (2012), dogs with skin lesions 
harboured strains of M. pachydermatis less susceptible to azoles in vitro than 
dogs without skin lesions. These observations, along with the results of our 
study, suggest that secondary Malassezia infections need a special approach for 
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evaluating in vitro susceptibility, and emphasise the importance of standardised 
methods for testing M. pachydermatis strains in veterinary medicine (Hector, 
2005; Cafarchia et al., 2012). 
In conclusion, all M. pachydermatis strains investigated in this study pro-
duced biofilms in vitro. Biofilms of all of the strains were much less susceptible 
to ketoconazole and itraconazole than their planktonic forms as demonstrated by 
the respective EC50 values. 
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